Jarvik Heart
Jarvik Heart is a privately held New York-based medical device company, founded in 1988, that develops the Jarvik 2200 artificial heart and related mechanical circulatory support devices for patients with severe or end-stage heart failure.
- Company typePrivate
- Founded1988
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Jarvik Heart does
Jarvik Heart is a privately held medical device company headquartered in New York and founded in 1988 by Robert Jarvik, a pioneering figure in artificial heart development. The firm specializes in mechanical circulatory support devices, with its primary product being the Jarvik 2200 artificial heart, introduced in 2023–2024 as part of the broader artificial organ and bionics market. The device targets patients with end-stage or severe heart failure who require mechanical circulatory support either as a bridge to transplant or as destination therapy when donor hearts are unavailable.
The company's underlying technology rests on ventricular assist device and total artificial heart engineering, with the Jarvik 2200 characterized in available sources as a novel-method-architecture design. Jarvik Heart operates with a small team of 51–100 employees, consistent with a clinical-stage or early-commercial medical device firm executing R&D, regulatory engagement, and limited manufacturing. Pricing is not publicly disclosed; medical devices of this class are typically monetized through hospital procurement channels and insurance reimbursement rather than direct patient sales.
Jarvik Heart's business model is anchored in regulated medical device commercialization: developing Class III implantable cardiac hardware, navigating FDA premarket pathways, and selling through specialty cardiac surgery centers and transplant programs. The company has limited publicly disclosed fundraising activity — a 2019 BIRD Foundation engagement is the only funding event on record, with $0 raised — and no customer logos, geographic markets, or distribution channel details are disclosed. Leadership comprises founder-CEO Robert Jarvik and COO Peter Hinchliffe, with no broader management team surfaced in the source material.
Jarvik Heart firmographics
Firmographics- Name
- Jarvik Heart
- Website
- https://jarvikheart.com
- Company type
- Private
- Founded year
- 1988
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Jarvik Heart is a privately held New York-based medical device company, founded in 1988, that develops the Jarvik 2200 artificial heart and related mechanical circulatory support devices for patients with severe or end-stage heart failure.
- Ownership category
- akta.pro rank
Jarvik Heart industry classification
Industry- Product category
- Mechanical Circulatory Support Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
- akta.pro secondary industries
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Heart Failure & Transplant Cardiology (HLAKABAD)
Keywords
Where Jarvik Heart is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Jarvik Heart business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure
Jarvik Heart product offering
Product offeringCore offering
Jarvik Heart develops and manufactures miniaturized mechanical circulatory support devices, principally the Jarvik 2200 artificial heart, for patients with end-stage heart failure who require long-term mechanical support as a bridge to transplant or destination therapy. The company sells implantable cardiac hardware to hospitals, cardiac surgery centers, and transplant programs.
Product overview
Jarvik Heart offers medical devices focused on mechanical circulatory support. The company's primary product is the Jarvik 2200 artificial heart, which provides long-term mechanical support for patients with severe heart failure.
Differentiator
Problem solved
Functional benefit
Products and services
- Jarvik 2200 artificial heart
Companies that use Jarvik Heart
Customer profileIdeal customer profiles1 record
Jarvik Heart technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Jarvik Heart partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights2 records
Jarvik Heart competitors and assessment
Company assessmentBroad incumbents
- Terumo: Terumo has cardiovascular and ventricular assist device programs through its Terumo Cardiovascular division. It is a broad incumbent whose mechanical circulatory support efforts and capital resources make it both a competitive threat and a potential strategic partner for Jarvik Heart.
- Medtronic: Medtronic acquired HeartWare International, giving it a mechanical circulatory support platform. As a broad incumbent in cardiac and vascular devices, Medtronic competes for the same end-stage heart failure market and represents potential strategic interest for Jarvik Heart's technology.
- Abbott: Abbott is the dominant player in mechanical circulatory support through the HeartMate 3 LVAD franchise and broader cardiovascular device portfolio. While its primary focus is LVADs rather than total artificial hearts, it sets the standard of care against which Jarvik Heart must compete and represents the most likely strategic acquirer.
- LivaNova: LivaNova is a cardiovascular device company with heart failure and mechanical circulatory support exposure. While it has divested some heart valve lines, its broader cardiovascular portfolio and capital base position it as a comparable broad incumbent in the same disease category.
Direct peers
- SynCardia Systems: SynCardia is the most directly comparable peer, developing the SynCardia Total Artificial Heart for end-stage biventricular heart failure. Both companies target the same patient population with similar mechanical circulatory support concepts, though SynCardia has established FDA status and a longer commercial history.
Emerging players
- ReliantHeart: ReliantHeart developed the HeartAssist5 (aVAD) ventricular assist device targeting advanced heart failure. As a smaller company focused on mechanical circulatory support, it is comparable to Jarvik Heart in scale and category focus.
- BiVACOR: BiVACOR is developing a total artificial heart using rotary blood pump technology, targeting the same end-stage heart failure population as Jarvik Heart. It represents an emerging competitor with significant government and venture backing, illustrating the capital scale required to compete in this category.
- Carmat: Carmat is developing a bioprosthetic total artificial heart targeting end-stage biventricular heart failure, making it a direct technological comparator to the Jarvik 2200. As a European-listed company, it provides a public-market reference point for total artificial heart development timelines and capital requirements.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Jarvik Heart social profiles
Digital presenceJarvik Heart financial estimates
Financial estimateRevenue estimate
Valuation estimate
Jarvik Heart leadership team
Management profileNumber of profiles
Profiles2 records
Jarvik Heart funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Jarvik Heart M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Jarvik Heart
What does Jarvik Heart do?
Jarvik Heart develops and manufactures miniaturized mechanical circulatory support devices, principally the Jarvik 2200 artificial heart, for patients with end-stage heart failure who require long-term mechanical support as a bridge to transplant or destination therapy. The company sells implantable cardiac hardware to hospitals, cardiac surgery centers, and transplant programs.
When was Jarvik Heart founded?
Jarvik Heart was founded in 1988. It employs 51 to 100 people.
Where is Jarvik Heart based?
Jarvik Heart is headquartered in New York, United States, in the North America region.
Who are Jarvik Heart's main competitors?
Broad incumbents on record are Terumo, Medtronic, Abbott and LivaNova. SynCardia Systems is listed as a direct peer. Emerging players are ReliantHeart, BiVACOR and Carmat.
Does Jarvik Heart have an API?
No public API is recorded for Jarvik Heart.
What industry is Jarvik Heart in?
Jarvik Heart's product category is Mechanical Circulatory Support Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.